Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 19Phase 1/2 11Phase 1 5Phase 4 3

Status

Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 7Genitourinary 6Plasma cell 3Dermatologic 2Thoracic 1Endocrine 1CNS 1

Conditions

Multiple Myeloma 2Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Dexamethasone 11Lenalidomide 10Bortezomib 10Zoledronic Acid 8ixazomib 4daratumumab 4Thalidomide 4Melphalan 4Cyclophosphamide 4tocilizumab 3Prednisone 3pomalidomide 2carfilzomib 2Kyphoplasty 2Filgrastim 2Doxorubicin 2Calcium Dobesilate 2zanubrutinib 1talquetamab 1pegylated granulocyte colony-stimulating factor 1montelukast 1isatuximab 1ibrutinib 1fludarabine phosphate 1fludarabine 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1apixaban 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Prednisone × Plasma cell × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT03829371 2025-12-03

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

University of Turin, Italy

Phase 4 Active not recruiting
450 enrolled
Plasma cell

Multiple Myeloma

NCT02773550 2020-01-18

Velcadito

Basque Health Service

Phase 4 Terminated
24 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡